Eli Lilly's (LLY) Retatrutide demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of Type 2 Diabetes
Importance
Level 1
- Retatrutide lowered A1C by an average of 1.7-2.0% at 40 weeks.
- Participants showed weight loss of up to 16.8%.
#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES